Danaos Corporation Announces Date for the Release of Third Quarter 2025 Results, Conference Call and Webcast
Prnewswire· 2025-11-06 12:30
Accessibility StatementSkip Navigation ATHENS, Greece, Nov. 6, 2025 /PRNewswire/ -- Danaos Corporation (NYSE: DAC), one of the world's largest independent owners of containerships, announced today that it will release its results for the third quarter ended September 30, 2025, after the close of the market in New York on Monday, November 17, 2025. The Company's management team will host a conference call to discuss the results on Tuesday, November 18, 2025 at 9:00 A.M. ET. About Danaos CorporationDanaos C ...
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Globenewswire· 2025-11-06 12:30
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial re ...
Cronos Group Reports 2025 Third Quarter Results
Globenewswire· 2025-11-06 12:30
Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS® remains the number one cannabis brand1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today annou ...
Solo Brands, Inc. Announces Third Quarter 2025 Results
Globenewswire· 2025-11-06 12:30
Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash FlowGRAPEVINE, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and nine months ended Se ...
Nasdaq Halts Robot Consulting Co., Ltd.

Globenewswire· 2025-11-06 12:30
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Robot Consulting Co., Ltd. (Nasdaq: LAWR) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PC from 04:00:00 on October 23, 2025 to 23:59:00 on November 5, 2025. The last sale price of the company’s ordinary shares was $3.75. More information about the SEC’s order can be found at https://www.sec.gov/f ...
Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan
CNBC· 2025-11-06 12:30
In this articleTSLAElon Musk, CEO of SpaceX and Tesla, attends the Viva Technology conference at the Porte de Versailles exhibition center in Paris on June 16, 2023.Gonzalo Fuentes | ReutersTesla is expected to announce on Thursday the results of a shareholder vote determining whether CEO Elon Musk should receive a pay package of nearly $1 trillion worth of stock over the next decade.There's little mystery to the outcome.The electric vehicle company has suggested that shareholders approve the plan. Between ...
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Prnewswire· 2025-11-06 12:30
Accessibility StatementSkip Navigation CAPLYTA, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications In pivotal trials, CAPLYTA did not increase mean weight gain, metabolic changes, or reported sexual side effects Experience the full interactive Multichannel News Release here: https://www.multivu.com/johnson-and- johnson/9355651-en-johnson-and-johnson-fda-approval-caplyta-lumateperone MDD, or clini ...
EDAP Reports Third Quarter 2025 Financial Results
Globenewswire· 2025-11-06 12:30
EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. ...
First Tellurium Subsidiary PyroDelta Delivers Thermoelectric-enhanced Combustion Engine to U.S. Airboat Manufacturer
Thenewswire· 2025-11-06 12:30
The initial sale opens a large and growing market for the modules.Vancouver, BC, Canada, November 6, 2025 – TheNewswire - First Tellurium Corp. (CSE: FTEL, OTC: FSTTF) reports that the Company’s subsidiary PyroDelta Energy Inc has entered a large new market for its thermoelectric modules designed originally to extend the range of high payload drones powered by combustion engines. “We have made an initial sale to a Florida-based airboat manufacturer,” said PyroDelta Head Engineer Michael Abdelmaseh. “This ...
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Prnewswire· 2025-11-06 12:30
Accessibility StatementSkip Navigation PRINCETON, N.J., Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its underwritten public offering. The offering was led by healthcare-focused, high-quality institutional investors and included participation from the Company's Chief Executive O ...